Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27199711 | 0.99 | BRD4 (0.30) | BRD4CREBBPTP53 | |
| SCHEMBL4873780 | 0.81 | LMNA (0.33) | BRD4CREBBPTP53ALDH1A1LMNA | |
| SCHEMBL27199727 | 0.80 | — | — | |
| SCHEMBL5608036 | 0.79 | ALDH1A1 (0.34) | BRD4CREBBPALDH1A1LMNAHPGD | |
| SCHEMBL30915810 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL27199724 | 0.79 | TRPV1 (0.31) | — | |
| SCHEMBL1455223 | 0.79 | NPC1 (0.36) | BRD4CREBBPTP53ALDH1A1LMNA | |
| SCHEMBL2388282 | 0.77 | NPC1 (0.35) | BRD4CREBBPTP53LMNASMN1; SMN2 | |
| SCHEMBL29669907 | 0.75 | NPC1 (0.32) | BRD4CREBBPTP53LMNASMN1; SMN2 | |
| SCHEMBL16393539 | 0.74 | PDK2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124618-A1 | Asymmetric Constrained Geometry Catalysts | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2024-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124618-A1 | Asymmetric Constrained Geometry Catalysts | GNE, ESR1, PGR | BRD4 3088/4885CREBBP 1216/4885TP53 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.